Gut Microbiome and Gastrointestinal Cancer les liaisons Dangereuses

Journal of Clinical Gastroenterology

Volumn 50, Issue , 2016, Pages S191-S196

  Tözün, Nurdan ^a   Vardareli, Eser ^a  

^a ACIBADEM UNIVERSITY   (Turkey)

Author keywords

cancer; gastrointestinal cancer; microbiome

Indexed keywords

DRUG; PREBIOTIC AGENT; PROBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG TARGETING; EPIGENETICS; ESCHERICHIA COLI; FUTUROLOGY; HUMAN; INTESTINE FLORA; LIVER CELL CARCINOMA; MICROBIOME; MICROFLORA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; UPPER GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; MICROBIOLOGY; PHYSIOLOGY; INFLAMMATION;

GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL NEOPLASMS; HUMANS; PROBIOTICS;

EID: 84995622102     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000714     Document Type: Article

References (46)

1. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90:859-904.
2. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449:804-810.
3. Aziz Q, DoréD, Emmanuel A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil. 2013;25:4-15.
4. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
5. Global Burden of Disease Cancer Collaboration. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505-527.
6. Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer: An overview. Cancer Lett. 2014;345:153-156.
7. Russell WR, Duncan SH, Flint HJ. The gut microbial metabolome: modulation of cancer risk in obese individuals. Proc Nutr Soc. 2013;72:178-188.
8. Johnson D. Enhancing the microbiome through diet, sleep, and exercise. Medscaper. 2016. http://www. medscape. com/view article/860179-2?nlid=102606-1521.
9. Cronin O, Molloy MG, Shanahan F. Exercise, fitness, and the gut. Curr Opin Gastroenterol. 2016;32:67-73.
10. Qiao L, Li X. Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now. Cancer Lett. 2014;345:150-152.
11. Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis. 2014;35:249-255.
12. Serban DE. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014;345:258-270.
13. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688-693.
14. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-180.
15. Kavanagh ME, O'Sullivan KE, O'Hanlon C, et al. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Lett. 2014;345:182-189.
16. Pei Z, Bini EJ, Yang L, et al. Bacterial biota in the human distal esophagus. Proc Natl Acad Sci USA. 2004;101: 4250-4255.
17. Wang ZK, Yang YS. Upper gastrointestinal microbiota and digestive diseases. World J Gastroenterol. 2013;19:1541-1550.
18. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117:60-69.
19. Sanduleanu S, Jonkers D, De Bruiène A, et al. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of proinflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15:1163-1175.
20. Hagiwara T, Mukaisho K, Nakayama T, et al. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development inMongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624-630.
21. Lofgren JL, Whary MT, Zhongming GE, et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology. 2011;140:210-220.
22. Lin C-J, Liao W-C, Lin H-J, et al. Statins attenuate Helicobacter pylori CagA translocation and reduce incidence of gastric cancer: in vitro and population-based case-control studies. PLoS One. 2016;11:e0146432.
23. Lai SW, Liao KF, Lin CY, et al. Statins on the risk of gastric cancer: A population-based observation in Taiwan. Am J Gastroenterol. 2013;108:147-149.
24. Wu XD, Zeng K, Xue FQ, et al. Statins are associated with reduced risk of gastric cancer: A meta-analysis. Eur J Clin Pharmacol. 2013;69:1855-1860.
25. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: A systematic review and meta-analysis. Ann Oncol. 2013;24:1721-1730.
26. Cao L, Yun J. Effect of Helicobacter pylori infection on the composition of gastric microbiota in the development of gastric cancer. Gastrointest Tumors. 2015;2:14-25.
27. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 2009;19:58-69.
28. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011;6:e16393.
29. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317-328.
30. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105:1907-1911.
31. Tjalsma J, Boleij A, Marchesi JR, et al. A bacterial driverpassenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10:575-582.
32. Parekh PJ, Balart LA, Johnson DA. The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. Clin Transl Gastroenterol. 2015;6:e91.
33. Newman J, Kosaka T, Sheppard BJ, et al. Bacterial infection promotes colon tumorigenesis in Apc(Min/+). J Infect Dis. 2001;184:227-230.
34. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016-1029.
35. Kado S, Uchida K, Funabashi H, et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor chain and p53 doubleknockout mice. Cancer Res. 2001;61:2395-2398.
36. Sobhani I, Jarrousse V, Guilemeau S, et al. Colon cancer patients' microbiome induces intestinal precancerous change in germ-free mice. Gut. 2011;60(suppl 3):A1.
37. Uronis JM, Jobin C. Microbes and colorectal cancer: is there a relationship? Curr Oncol. 2009;16:23-24.
38. Beutler BA. TLRs and innate immunity. Blood. 2009;113: 1399-1407.
39. Akn H, Tözün N. Diet, microbiota, and colorectal cancer. J Clin Gastroenterol. 2014;48(suppl 1):67-69.
40. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:801-812.
41. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504-516.
42. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422-433.
43. Tao X, Wang N, Qin W. Gut microbiota and hepatocellular carcinoma. Gastrointest Tumors. 2015;2:33-40.
44. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141: 1220-1230. 1230. e1-3.
45. Farrell JJ, Zhang L, Zhou Hui, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61:582-588.
46. Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 2014;345:157-163.